Biography
Dr. Tommaso Pollini, M.D. is a post-doctoral research fellow at the University of California, San Francisco (UCSF) in the Maker Lab, specializing in pancreatic cystic neoplasms with a focus on Intraductal Papillary Mucinous Neoplasms (IPMN). He completed his surgical training at the Pancreas Institute of the University of Verona, Italy, where he developed a solid foundation in pancreatic diseases. Recognized for his contributions to the field, Dr. Pollini received the prestigious Kenneth Warren Fellowship from the International Hepato-Pancreato-Biliary Association and the Steve Sotsky Award from the American Hepato-Pancreato-Biliary Association.
At UCSF, his research centers on developing predictive models for high-grade dysplasia in pancreatic cystic tumors using machine learning. Utilizing his expertise in bioinformatics, single-nucleus RNA sequencing (snRNAseq), and spatial transcriptomics, he studies the tumor immune microenvironment of pancreatic cancers. Dr. Pollini has published his work in leading journals such as JAMA Surgery, The Lancet Gastroenterology & Hepatology, and Gastroenterology, contributing significantly to advancements in pancreatic cancer research.
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of Verona | General Surgery Residency | 01/2023 | |
University of Verona | Research Fellow at the Department of General and Pancreatic Surgery of the Pancreas Institute | 12/2017 | |
University of Verona | MD | Medicine | 10/2015 |
Awards & Honors
Award | Conferred By | Date |
---|---|---|
Kenneth Warren Fellowship | International Hepato-Pancreato-Biliary Association (IHPBA) | 2021/2022 |
Steve Sotksi Award | American Hepato-Pancreato-Biliary Association (AHPBA) | 2021 |
Publications
- Impact of coronary artery stenting on perioperative mortality and complications in patients undergoing pancreaticoduodenectomy.| | PubMed
- ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.| | PubMed
- ASO Author Reflections: Is Adjuvant Therapy Necessary for All Patients with Invasive Mucinous Cystic Neoplasms of the Pancreas? Let's De-escalate.| | PubMed
- Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.| | PubMed
- Impact of age, comorbidities and relevant changes on surveillance strategy of intraductal papillary mucinous neoplasms: a competing risk analysis.| | PubMed
- Pancreas Cyst Diagnosis and Advances in Cyst Fluid Analysis.| | PubMed
- Reply.| | PubMed
- Intraoperative hepatic artery infusion pump perfusion testing with indocyanine green near-infrared imaging offers multiple potential advantages.| | PubMed
- "Mickey Mouse sign" to identify and remove cystic duct stones in postcholecystectomy syndrome.| | PubMed
- Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.| | PubMed